Alkeon Capital Management’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Alkeon Capital Management’s Portfolio TPTX Stock Details TPTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-626,046	Closed	-$41.6M	–	183
2021 Q3	$41.6M	Sell	626,046 -1,267	-0.2%	-$90.3K	0.07%	122
2021 Q2	$48.9M	Sell	627,313 -1,756	-0.3%	-$130K	0.07%	120
2021 Q1	$59.5M	Buy	629,069 +1,118	+0.2%	+$133K	0.09%	115
2020 Q4	$76.5M	Buy	627,951 +150,951	+32%	+$16.5M	0.12%	104
2020 Q3	$41.7M	Hold	477,000	–	–	0.08%	104
2020 Q2	$30.8M	Buy	477,000 +20,000	+4%	+$1.15M	0.08%	109
2020 Q1	$20.4M	Buy	457,000 +100,000	+28%	+$5.31M	0.09%	108
2019 Q4	$22.2M	Sell	357,000 -200,000	-36%	-$9.52M	0.08%	103
2019 Q3	$20.9M	Hold	557,000	–	–	0.07%	111
2019 Q2	$22.7M	Buy	+557,000	New	+$19.9M	0.09%	110

Other funds holding TPTX

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Alkeon Capital Management's TPTX Position: Q4 2021 in Review

Alkeon Capital Management sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q4 2021, closing a stake of 626,046 shares — an estimated $41.6M sold.

Alkeon Capital Management first reported a position in TPTX in Q2 2019 and held it in 10 quarters. The position peaked at $76.5M in Q4 2020. 172 funds tracked by Wall St. Rank hold TPTX as of Q4 2021.

Alkeon Capital Management reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
Alkeon Capital Management sold 626,046 Turning Point Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $41.6M.
Alkeon Capital Management first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q2 2019 and held it in 10 quarters.
Alkeon Capital Management's Turning Point Therapeutics, Inc. Common Stock position peaked at $76.5M in Q4 2020.
172 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q4 2021.

Based on Alkeon Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.